

The "Ansel reference"



Pharmaceutical Dosage Forms and Drug Delivery Systems

Howard C. Ansel, Ph.D.

Panz Professor of Pharmacy, Department of
Pharmaceutics, College of Pharmacy
The University of Georgia

Nicholas G. Popovich, Ph.D.

Professor and Head, Department of Pharmacy
Practice, School of Pharmacy and Pharmacal
Sciences
Purdue University

Loyd V. Allen, Jr., Ph.D.

Professor and Chair, Department of Medicinal
Chemistry and Pharmaceutics, College of
Pharmacy
The University of Oklahoma

SIXTH EDITION

A Lea & Febiger Book



Williams & Wilkins

1875 Chestnut Street • Philadelphia, Pennsylvania 19103
A Division of Williams & Wilkins Company
350 Madison Avenue • New York, New York 10017





BEST AVAILABLE COPY

© 1994 by the American Medical Association
Developmental Therapeutics Division, Medical
Products Branch, National Cancer Institute,
National Institutes of Health, Bethesda, Maryland

Copyright © 1994
Williams & Wilkins
Rose Tree Corporate Center, Building
1400 North Providence Road, Suite 500/55
Media, PA 19063-2043 USA



All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form—by any means, including photocopying—or utilized by any information storage and retrieval system without written permission from the copyright owner.

Accurate indications, adverse reactions, and dosage schedules for drugs are provided in the book, but it is possible they may change. The reader is urged to review the package information data of the manufacturers of the medications mentioned.

Printed in the United States of America

Library of Congress Cataloguing-in-Publication Data

94-3798
c. 1994. \$30.00

Ansel, Howard C., 1933-
Pharmaceutical dosage forms and drug delivery systems / Howard C. Ansel, Nicholas G. Popovich, Lloyd V. Allen, Jr., 6th ed.

p. cm.

Includes bibliographical references and index.

ISBN 0-683-04193-0

1. Drugs—Dosage forms. 2. Drug delivery systems.

1. Popovich, Nicholas G. II. Allen, Lloyd V. III. Title.

[DNLM: 1. Dosage forms. 2. Drug delivery systems. QV17.S8.A68
1994]

RS250.A57—1994

617.1 .A620

DNLM-DLC

60 Library of Congress

94-3798

v. D

The use of portions of the text of USP®/NF®/USP® copyright 1994 is by permission of the USP Convention. The Convention is not responsible for any inaccuracy of reproduction or for any type of medical interpretation that may arise from separation of concepts from the original context or by consequence resulting from publication of a supplement.

© 1994 by the American Medical Association

BEST AVAILABLE COPY

Chapter 3: Principles of Pharmacokinetics 61




Fig. 3-2. Active transport mechanism. D represents a drug molecule; C represents the carrier in the membrane. (After O'Reilly, W.F., *Arch. J. Pharm.*, 47, 968, 1966.)

onization
ant effect
sociation
the drug.
tain level
area, the
stribution,
xitation in
following

iged, and

following

d using:

ated by:

ration of a

A solution?

Facilitated transport, as a subclassification of specialized transport, denotes a process with the additional feature of the solute or drug being moved across the membrane against a concentration gradient, that is, from a solution of lower concentration to one of a higher concentration or, if the solute is an ion, against an electrochemical potential gradient. In contrast to active transport, *facilitated diffusion* is a specialized transport mechanism having all of the above characteristics except that the solute is not transferred against a concentration gradient and may attain the same concentration inside the cell as that on the outside.

Many body nutrients, as sugars and amino acids, are transported across the membranes of the gastrointestinal tract by carrier processes. Certain vitamins, as thiamine, niacin, riboflavin and vitamin B₆, and drug substances as methyl dopa and 5-fluorouracil, require active transport mechanisms for their absorption.

Investigations of intestinal transport have often utilized *in situ* (at the site) or *in vivo* (in the body) animal models or *ex vivo* (outside the body) transport models; however, recently cell culture models of human small-intestine absorptive cells have become available to investigate transport across intestinal epithelium.¹ Both passive and transport-mediated studies have been conducted to investigate mechanisms as well as rates of transport.

Dissolution and Drug Absorption

In order for a drug to be absorbed, it must first be dissolved in the fluid at the absorption site,

for instance, a drug administered orally as tablet or capsule form cannot be absorbed until the drug particles are dissolved by the fluids at some point within the gastrointestinal tract. In instances in which the solubility of a drug is dependent upon either an acidic or basic medium, the drug would be dissolved in the stomach or intestines, respectively (Fig. 3-3). The process by which a drug particle dissolves is termed *dissolution*.

As a drug particle undergoes dissolution, the drug molecules on the surface are the first to enter into solution creating a saturated layer of drug solution which envelops the surface of the solid drug particle. This layer of solution is referred to as the *diffusion layer*. From this diffusion layer, the drug molecules pass throughout the dissolving fluid and make contact with the biologic membranes and absorption ensues. As the molecules of drug continue to leave the diffusion layer, the layer is replenished with dissolved drug from the surface of the drug particle and the process of absorption continues.

If the process of dissolution for a given drug particle is rapid, or if the drug is administered as a solution and remains present in the body as such, the rate at which the drug becomes absorbed would be primarily dependent upon its ability to traverse the membrane barrier. However, if the rate of dissolution for a drug particle



Fig. 3-3. Anatomical diagram showing the digestive system including the locations of the stomach, liver, gallbladder, pancreas, and rectum.

BEST AVAILABLE COPY

and may vary by factor of the physicochemical characteristics of the drug substance or the dosage form. The dissolution process itself would be a rate-limiting step in the absorption process. Slowly soluble drugs such as digoxin may not only be absorbed at a slow rate, they may be incompletely absorbed, or in some cases largely unabsorbed following oral administration due to the natural limitation of time that they may remain within the stomach or the intestinal tract. Thus, poorly soluble drugs or poorly formulated drug products may result in a drug's incomplete absorption and its passage unchanged, out of the system via the feces.

Under normal circumstances a drug may be expected to remain in the stomach for 2 to 4 hours (gastric emptying time) and in the small intestines for 4 to 10 hours, although there is substantial variation between people, and even in the same person on different occasions. Various techniques have been used to determine gastric emptying time and the gastrointestinal passage of drug from various oral dosage forms, including the tracking of dosage forms labeled with gamma emitting radionuclides through gamma scintigraphy. The gastric emptying time for a drug is most rapid with a fasting stomach, becoming slower as the food content is increased. Changes in gastric emptying time and/or in intestinal motility can affect drug transit time and thus the opportunity for drug dissolution and absorption.

These changes can be effected by drugs the patient may be taking. Certain drugs with anti-cholinergic properties, e.g., dicyclomine HCl, amitriptyline HCl, have the ability to slow down gastric emptying. This can enhance the rate of absorption of drugs normally absorbed from the stomach, and reduce the rate of absorption of drugs that are primarily absorbed from the small intestine. Alternatively, drugs which enhance gastric motility, e.g., laxatives, may cause some drugs to move so quickly through the gastrointestinal system and past their absorptive site at such a rate to reduce the amount of drug actually absorbed. This effect has been demonstrated with digoxin, whose absorption is significantly decreased by accelerating gastrointestinal motility.

The aging process itself may also influence gastrointestinal absorption. In the elderly, gastric acidity, the number of absorptive cells, intestinal blood flow, the rate of gastric emptying and intestinal motility are all decreased. It appears,

therefore, that drugs for which absorption is dependent upon passive processes are not affected by these factors as much as those that are dependent upon active transport mechanisms, e.g., alginates, taurine, sugars. A decrease in gastric emptying time would be advantageous for those drugs that are absorbed from the stomach but disadvantageous for those drugs which are prone to acid degradation, e.g., penicillins, erythromycin or inactivated by stomach enzymes, e.g., dopa.

The dissolution of a substance may be described by the modified Noves-Whitney equation:

$$\frac{dc}{dt} = kS(c_s - c)$$

in which $\frac{dc}{dt}$ is the rate of dissolution, k is the dissolution rate constant, S is the surface area of the dissolving solid, c_s is the saturation concentration of drug in the diffusion layer (which may be approximated by the maximum solubility of the drug in the solvent since the diffusion layer is considered saturated), and c , is the concentration of the drug in the dissolution medium at time t ($c_s - c$ is the concentration gradient). The rate of dissolution is governed by the rate of diffusion of solute molecules through the diffusion layer into the body of the solution. The equation reveals that the dissolution rate of a drug may be increased by increasing the surface area (reducing the particle size) of the drug, by increasing the solubility of the drug in the diffusion layer, and by factors embodied in the dissolution rate constant, k , including the intensity of agitation of the solvent and the diffusion coefficient of the dissolving drug. For a given drug, the diffusion coefficient and usually the concentration of the drug in the diffusion layer will increase with increasing temperature. Also, increasing the rate of agitation of the dissolving medium will increase the rate of dissolution. A reduction in the viscosity of the solvent employed is another means which may be used to enhance the dissolution rate of a drug. Changes in the pH or the nature of the solvent which influence the solubility of the drug may be used to advantage in increasing dissolution rate. Effervescent, buffered aspirin tablet formulations use some of these principles to their advantage. Due to the alkaline adjuvants in the tablet, the solubility of the aspirin is enhanced within the diffusional